1757 related articles for article (PubMed ID: 17605511)
21. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Uemura K; Kakuta T
Clin Calcium; 2010 Jul; 20(7):1104-10. PubMed ID: 20585190
[TBL] [Abstract][Full Text] [Related]
22. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
23. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of the pharmacotherapy of secondary hyperparathyroidism (SHPT) in grades 3-5 Chronic Kidney Disease (CKD).
Miedziaszczyk M; Idasiak-Piechocka I; Wiśniewski OW; Lacka K
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):232-239. PubMed ID: 35049000
[TBL] [Abstract][Full Text] [Related]
26. Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the "U".
Cozzolino M; Brandenburg V
Clin Nephrol; 2009 Jun; 71(6):593-601. PubMed ID: 19473626
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-Dialysis.
Snyder S; Hollenbeak CS; Kalantar-Zadeh K; Gitlin M; Ashfaq A
Forum Health Econ Policy; 2020 Mar; 23(1):. PubMed ID: 32134730
[TBL] [Abstract][Full Text] [Related]
28. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
Front Public Health; 2021; 9():712027. PubMed ID: 34368073
[No Abstract] [Full Text] [Related]
29. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
Nuijten M; Andress DL; Marx SE; Sterz R
Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
[TBL] [Abstract][Full Text] [Related]
30. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
31. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
[TBL] [Abstract][Full Text] [Related]
32. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
33. Secondary hyperparathyroidism in chronic kidney disease: focus on clinical consequences and vitamin D therapies.
Hudson JQ
Ann Pharmacother; 2006 Sep; 40(9):1584-93. PubMed ID: 16912241
[TBL] [Abstract][Full Text] [Related]
34. Role of cinacalcet in management of mineral bone disorder in chronic kidney disease (control of calcium, phosphorus and parathyroid hormone).
Tahara H
Ther Apher Dial; 2008 Oct; 12 Suppl 1():S27-33. PubMed ID: 19032524
[TBL] [Abstract][Full Text] [Related]
35. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
36. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
37. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
Nakai K; Komaba H; Fukagawa M
Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
[TBL] [Abstract][Full Text] [Related]
38. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
[TBL] [Abstract][Full Text] [Related]
39. Short-term use of cinacalcet in children on regular hemodialysis.
Youssef D
Arab J Nephrol Transplant; 2012 Jan; 5(1):51-3. PubMed ID: 22283867
[TBL] [Abstract][Full Text] [Related]
40. Differential influence of vitamin D analogs on left ventricular mass index in maintenance hemodialysis patients.
Sezer S; Tutal E; Bal Z; Uyar ME; Bal U; Cakir U; Acar NO; Haberal M
Int J Artif Organs; 2014 Feb; 37(2):118-25. PubMed ID: 24619898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
